Dr. Hani M. Babiker, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 701
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME142546 -
Hospitalist Physician
AZ license 42076 -
Internal Medicine Physician
NY license 250230
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Jacksonville, FL
Medical groups
- Mayo Clinic Jacksonville (1,615 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 701
- Services billed
- 114,053
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 14,820 | 22 |
| Injection, nivolumab, 1 mg | 10,560 | 21 |
| Injection, pembrolizumab, 1 mg | 10,000 | 37 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 9,180 | 18 |
| Injection, fosaprepitant, 1 mg | 8,250 | 44 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 7,380 | 25 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 6,825 | 16 |
| Injection, oxaliplatin, 0.5 mg | 5,000 | 16 |
| Injection, paclitaxel, 1 mg | 4,002 | 18 |
| Injection, denosumab, 1 mg | 3,180 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Jacksonville, FL | 18 |
| Prochlorperazine Maleate Other prescribers in Jacksonville, FL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 20 payments worth $8,439 in total to this clinician.
| Ipsen Biopharmaceuticals, Inc | $6,401 |
|---|---|
| Novocure Inc. | $2,037 |
| Consulting Fee | $6,090 |
|---|---|
| Travel and Lodging | $1,298 |
| Food and Beverage | $1,051 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc Feb 21, 2025 | Consulting Fee | $3,480 |
| Ipsen Biopharmaceuticals, Inc Jan 9, 2025 | Consulting Fee Onivyde · Oncology | $2,610 |
| Novocure Inc. Oct 30, 2025 | Travel and Lodging travel to Dallas, TX | $906 |
| Novocure Inc. Nov 8, 2025 | Travel and Lodging travel to Dallas, TX | $368 |
| Novocure Inc. Nov 9, 2025 | Travel and Lodging travel to Dallas, TX | $20.93 |
| Novocure Inc. Oct 30, 2025 | Travel and Lodging travel to Dallas, TX | $3.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $730,564 in research payments for these studies, mostly to the institutions running them.
- Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05245500 - Tumor Treating Fields Effect on Pancreatic Adenocarcinoma Desmoplastic Tumor Microenvironment and Therapeutic Impact
Novocure GmbH - A study of KK2269 in adult participants with solid tumors
Kyowa Kirin Co., Ltd - NOVOTTF-100L -a Phase I/Ib trial, single-center, non-randomized, open-label study of Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) and G+TTF maintenance therapy …
Novocure Inc. - A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent H…
AstraZeneca Pharmaceuticals LP - EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma
Novocure Inc. - Atezolizumab and bevacizumab tiragolumab in 1L unresectable hcc pts
Genentech, Inc. - A Phase III,Randomized,Double Blind,Placebo Controlled,Multicenter,Global Study of Rilvegostomig in Combination with Chemotherapy as Adjuvant Treatment in Adult Participants After Resection of Biliary Tract Cancer wit…
AstraZeneca Pharmaceuticals LP - A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Un…
Incyte Corporation - A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patien…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.